These findings, together with the unfavorable prognosis of DLBCL patients showing high <i>RAB7A</i> expression, suggest that targeting RAB7 is a promising therapeutic approach for mature B cell-derived lymphomas. This evidence concerns the gene RAB7A and lymphoma.